Baylor Scott & White Health Plan to exit Medicaid, individual markets; cut 321 jobs
Jakob Emerson / beckershospitalreview - Baylor Scott & White Health Plan said April 14 it will exit the Texas Medicaid managed care market and discontinue its individual marketplace plans, affecting roughly 225,000 members and eliminating 321 jobs statewide, according to the Dallas Morning News…
AI Summary: Baylor Scott & White announced it will leave Medicaid individual markets, a move that will shed hundreds of jobs and reshape coverage options for affected enrollees. The decision highlights ongoing financial pressures in public‑program participation and raises practical concerns about access continuity for people reliant on those plans.
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Marissa Plescia / medcitynews - Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased.The post New Bill Seeks to Lower Out-of-Pocket Drug…
AI Summary: Lawmakers introduced legislation to reduce out‑of‑pocket drug costs by allowing patients' direct drug purchases to count toward their insurance deductibles. The proposal aims to ease financial strain for people buying costly medications out‑of‑pocket, but would require insurers and pharmacy systems to change longstanding accounting and benefits practices.
Insmed shelves Brinsupri in skin disease after mid-stage flop
Elizabeth Cairns / endpoints - Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill in sinus inflammation at the end of last year. The ...
AI Summary: Insmed announced it will halt development of Brinsupri for a dermatologic indication following disappointing mid‑stage trial results. Company commentary stressed the skin setback does not negate Brinsupri’s potential in pulmonary indications, but investors and clinicians will understandably ask for clearer signs of life before buying the comeback story.
High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…
AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.
Orlando Health fleshes out Alabama footprint with another acquisition
fiercehealthcare - The $10 billion nonprofit plans to acquire RMC Health System from the City of Anniston, building on 2024's big-ticket purchase of five Alabama hospitals from Tenet Healthcare.
AI Summary: Orlando Health continued its regional growth by acquiring an Alabama health system, extending its clinical and operational footprint into the state. The move aims to integrate services, expand care access and consolidate regional networks as health systems seek scale to manage costs and enhance specialty offerings.
Patients Are Using Chatbots to Fight Medical Bills, With Mixed Results
Sarah Kwon / nytimes - While chatbots like Claude and ChatGPT can help narrow the information divide between patients and providers, they can also dispense flawed advice.
AI Summary: Patients increasingly use AI chatbots to challenge medical bills, leveraging automated appeals and negotiation scripts. While chatbots can speed administrative tasks and sometimes reduce balances, outcomes vary and users face inconsistent accuracy and limits in handling complex payer disputes—so yes, convenience at the price of occasional frustration.
Hospital M&A roars back to life in Q1 2026; Operating performances fray in February
fiercehealthcare - The first quarter of 2026 extended a recovery from last year's dealmaking slowdown with 22 newly announced transactions, largely fueled by divestitures. Meanwhile, February benchmarking data outlined persistent operating pressures and soft volumes.
AI Summary: Hospital merger and acquisition activity rebounded sharply in Q1 2026 after a 2025 slowdown, driven by systems seeking scale to manage financial stress. Reports show operating performance weakened in February, prompting consolidation as a survival strategy; expect more deal-making as health systems chase efficiencies and revenue stability in a tight market.
- Closures and bailouts: struggling hospitals prompt local interventions (3)
- Local deals: hospitals change hands, campuses expand, LOIs signed (4)
- M&A resurgence: systems consolidate as operating pressure mounts (5)
- Operational fixes: CEOs tighten capital, redefine growth, stabilize workforce (5)
- All Other Stories
Closures and bailouts: struggling hospitals prompt local interventions
Local deals: hospitals change hands, campuses expand, LOIs signed
M&A resurgence: systems consolidate as operating pressure mounts
Operational fixes: CEOs tighten capital, redefine growth, stabilize workforce
All Other Stories
CMS proposes mandatory hospital-bundled model for joint replacements
Ella Jeffries / beckershospitalreview - CMS is proposing a mandatory, nationwide episode-based payment model for joint replacements that would hold most hospitals responsible for Medicare spending tied to a patient’s surgery and recovery. Beginning Oct. 1, 2027, the model — referred to as CJR-X…
AI Summary: CMS unveiled a plan to make hospitals participate in a mandatory bundled-payment model for joint replacement surgeries, offering a 2.4% payment increase tied to the new program. The proposal would standardize payment and care pathways nationwide, shifting financial and operational risk onto hospitals while aiming to curb costs and improve outcomes.
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.
AbbVie sues HHS over 340B patient definition
Ella Jeffries / beckershospitalreview - AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on guidance issued in 1996, allows covered entities to claim …
AI Summary: AbbVie has filed suit challenging HHS’s interpretation of the 340B program, arguing the agency’s “patient” definition and related guidance are outdated and legally flawed. The company seeks judicial clarity that could reshape who qualifies for discounted drugs and how hospitals and manufacturers navigate the program — yes, the pricing drama continues.
RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
fiercehealthcare - Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he said have made “many of us ... come to the conc…
AI Summary: Robert F. Kennedy Jr. is debuting a health-focused podcast promising to call out what he characterizes as hypocrisy and corruption in medicine and public health. The show aims to amplify skeptical takes on mainstream health institutions and policies, positioning itself as a combative platform for contrarian voices and investigations.
Digital health startups raked in $4B during Q1 with 12 megadeals driving investment: Rock Health
fiercehealthcare - Digital health startups pocketed $4 billion in venture capital funding in the first quarter of 2026, marking the strongest first quarter since the pandemic peak.
AI Summary: Venture investment in digital health is narrowing: a small number of startups captured a large share of Q1 funding, driven by a handful of megadeals. The trend signals investor preference for later‑stage companies and scale plays, squeezing early innovators who must now demonstrate clearer paths to durable revenue and clinical impact.
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio
oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]
AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Memorial Hermann goes out of network with BCBS Texas
Elizabeth Casolo / beckershospitalreview - Houston-based Memorial Hermann Health System’s contract with BCBS Texas expired April 1, rendering the health system out of network. Commercial and ACA exchange (both individual and family) plan members lost access at the end of March. Memorial Hermann ha…
AI Summary: Memorial Hermann and Blue Cross Blue Shield of Texas failed to agree on a new contract, resulting in the health system going out of network for affected plan members. Patients face potential higher costs and care disruptions while negotiators jockey publicly; both sides warn of financial stakes and urge members to stay informed.
White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
fiercehealthcare - The requested budget cut is about half of what the administration asked, and was denied, last year. However, plans for reorganizing agencies under an Administration for a Healthy America persist, as do calls to eliminate various programs and centers the W…
AI Summary: The administration has floated a plan to cut HHS funding by roughly 12–12.5% in FY2027 while pursuing agency reorganization. The proposal targets discretionary programs including research funding, prompting scientific groups to urge Congress to reject the NIH reductions and warn of downstream impacts on biomedical research and patient care.
- Researchers, cancer groups warn NIH cuts will harm patients (6)
- White House pushes deep HHS cuts, agency reorganization (4)
- All Other Stories
Researchers, cancer groups warn NIH cuts will harm patients
White House pushes deep HHS cuts, agency reorganization
All Other Stories
Why 131 Hospitals Are Suing HHS Over Alleged Underpayment
Katie Adams / medcitynews - A group of 131 hospitals has sued HHS over a CMS policy they say improperly reduces Medicare disproportionate share hospital (DSH) payments. The lawsuit is the latest in a decade-long legal battle over how the agency counts patient days and calculates pay…
AI Summary: One hundred thirty‑one hospitals have filed suit challenging HHS’s 2023 Disproportionate Share Hospital calculation, arguing the agency’s formula undercounts uncompensated care and systematically underpays safety‑net providers. The plaintiffs seek to overturn the rule and recover alleged shortfalls, warning that ongoing underpayment threatens hospital finances and patient access.